| Literature DB >> 19157546 |
Hiroaki Goto1, Takuya Naruto, Reo Tanoshima, Hiromi Kato, Tomoko Yokosuka, Masakatsu Yanagimachi, Hisaki Fujii, Shumpei Yokota, Hiromi Komine.
Abstract
Sensitivity to 10 anticancer drugs was evaluated in 6 childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cell lines. Authenticity of newly established cell lines was confirmed by genomic fingerprinting. The line YCUB-5R established at relapse was more resistant to 4-hydroperoxy-cyclophosphamide, cytarabine, L-asparaginase, topotecan, fludarabine, and etoposide than YCUB-5 from the same patient at diagnosis. Of the drugs tested, etoposide and SN-38 (irinotecan) showed highest efficacy in the panel, with 50% growth inhibition at 0.22-1.8 microg/ml and 0.57-3.6 ng/ml, respectively. This cell line panel offers an in vitro model for the development of new therapies for childhood BCP-ALL.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19157546 DOI： 10.1016/j.leukres.2008.12.003
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156